Tulane Home Tulane Shield logo linking to site home page

Prostate Clinical Trials

Molecularly Targeted Radiation Trials
 

AAA
Phase 1/2 Open-Label, Multi-Center, Dose-Escalation Study of Safety, Tolerability, Pharmacokinetics, Dosimetry, and Response to Repeat Dosing of 177Lu-PSMA-R2 Radio-Ligand Therapy in Patients with Prostate Specific Membrane Antigen (PSMA) Positive (68Ga-PSMA-R2) Progressive Metastatic Castration-Resistant Prostate Cancer, Following Previous Systemic Treatment
More Information

ARROW        
A multicenter, Randomized, controlled phase 2 study: Efficacy and safety of I-131-1095 Radiotherapy in combination with enzalutamide in metastatic castration-resistant prOstate cancer (mCRPC) patients Who are 18F-DCFPyL prostate-specific membrane antigen (PSMA)-avid, chemotherapy-naïve, and progressed on abiraterone
More Information

BED IIT-382    
Changes in 18F-fluciclovine Positron Emission Tomography (PET) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate: A Pilot Study
More Information

ESCALATE
A Phase III Randomized Study Comparing Enzalutamide or Darolutamide with Radium-223 vs Enzalutamide or Darolutamide with Placebo and the Effect upon Symptomatic Skeletal Event-Free Survival for mCRPC Patients
More Information

69086420PCR1001
A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
More Information

BAY16996
A Phase 4 Long-Term Follow-Up Study to Define the Safety Profile of Radium-223 Dichloride
More Information

FIREFLY
68Ga-PSMA-11 Patients with Newly Diagnosed and Recurrent Prostate Cancer
More Information

JNJ-69086420
A Phase I Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
More Information

NiraRad
Phase 1B Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
More Information

PSMAfore
A Phase III, Open-Label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naive Men with Progressive Metastatic Castrate Resistant Prostate Cancer
More Information

SPLASH
STudy Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-Line Hormonal Treatment
More Information

 

Other Prostate Cancer Trials

NU 17U19
Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer
More Information

TUHC 07/25/13 - Genetics of Prostate Cancer

IRONMAN
Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)
More Information

Merck 641
A Phase 3, Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
More Information

C17-191         
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in Metastatic Castration Sensitive Prostate Cancer with and without DNA Repair Mutations. (CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone.)
More Information

AMGEN 509
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
More Information

AMGEN 160
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-Life Extended Bispecific T-Cell Engager AMG 160 in Subjects with Metastatic Castration-Resistant Prostate Cancer
More Information

ARV-110-mCRPC-101
A Phase 1/2, open-label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration resistant prostate cancer
More Information

PLANETTE
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations
More Information

AR-V7
Prevalence of AR-V7 in African American Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Novel Hormonal Agents

NRG GU008
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
More Information

PANTHER
Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer
More Information

PROMISE
PROstate Cancer Precision Medicine Multi-Institutional Collaborative Effort: The PROMISE Study